SPTBN2

Across TCGA pan-cancer cohorts, SPTBN2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated SPTBN2 data layer compared with 24 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher SPTBN2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated SPTBN2 expression acts as an unfavorable survival marker, although some lineages such as UCEC and GBM show a favorable association.

UCEC, CCRCC, and PDAC are the cancer types where SPTBN2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	OS	Tertile	II,III,IV	1.000	0.553	.018	16	view →
CCRCC	DFS	Median	All	0.709	1.000	.010	12	view →
PDAC	OS	Median	II,III,IV	0.273	0.435	.006	11	view →
GBM	DFS	Quartile	All	0.856	0.590	.005	9	view →
LUAD	DFS	Median	II,III,IV	0.285	0.788	.011	5	view →
LSCC	DFS	Median	All	0.983	0.893	.016	4	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

SPTBN2–UCEC (OS)

Open the UCEC breakdown →